山外山(688410.SH):一季度耗材板塊保持持續高增長 同比增長30%
格隆匯5月16日丨山外山(688410.SH)披露投資者關係活動記錄表顯示,依託山外山公司的產業基礎、科研平台及資源優勢,山外山公司旗下子公司天外天、德萊福不斷強化科技研發、產品品質、生產製造等發展基礎及軟硬實力,陸續取得了血液透析液/粉、血液透析器、透析液過濾器、連續性血液淨化管路、血液灌流器等系列血液淨化耗材的註冊證,已基本完成自產血液淨化耗材的全線佈局。
自產血液淨化耗材的全面上線對山外山公司進一步拓寬市場具有重要意義——開啟了公司“設備+耗材並駕齊驅、比翼雙飛”協同效應與馬太效應的發展新篇章,全產業鏈協同競爭優勢明顯,為臨牀提供全面的血液淨化整體解決方案,帶動了公司業績的高增長。
2023年度公司血液淨化耗材板塊實現收入1.02億元,同比增長32.99%,2024年一季度耗材板塊保持持續高增長,同比增長30%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.